Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Q2 Sales $34.887M Beat $32.283M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:26pm
RxSight (NASDAQ:RXST) reported quarterly sales of $34.887 million which beat the analyst consensus estimate of $32.283 million by 8.07 percent. This is a 67.65 percent increase over sales of $20.810 million the same period last year.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist